9月13日,在2026世界肺癌大会首日上午首场主席论坛上,翰森制药(03692.HK)自主研发的B7-H3靶向ADC——瑞康立伏妥塔单抗(研发代号:HS-20093),以最新突破性摘要形式亮相并作口头报告。 这次公布的数据,瑞康立伏妥塔单抗刷新了小细胞肺癌(SCLC)二线治疗最长总生存期(OS)纪录。 本次大会发布的是瑞康立伏妥塔单抗针对复发性小细胞肺癌的III期ARTEMIS-008研究的...
Source Link9月13日,在2026世界肺癌大会首日上午首场主席论坛上,翰森制药(03692.HK)自主研发的B7-H3靶向ADC——瑞康立伏妥塔单抗(研发代号:HS-20093),以最新突破性摘要形式亮相并作口头报告。 这次公布的数据,瑞康立伏妥塔单抗刷新了小细胞肺癌(SCLC)二线治疗最长总生存期(OS)纪录。 本次大会发布的是瑞康立伏妥塔单抗针对复发性小细胞肺癌的III期ARTEMIS-008研究的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.